Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

JGM 2017: Factors influencing adherence in CML and ways to improvement (Jana Pelouchová)

Jana Pelouchova

 

 

  

         

 

Factors influencing adherence in CML and ways to improvement:
Results from a patient-driven survey of 2,546 patients in 63 countries
Jana Pelouchová, European Cancer Patient Coalition (ECPC), Czech Republic 

  • CML Advocates Network: Patients creating scientific evidence
  • Why this study?
  • Where are we now?
  • Truly global research: 2,546 patients from 63 countries
  • Validated adherence scales to classify patients into levels of adherence
  • Results on adherence levels
  • What can we do to drive adherence?
  • Conclusions

Virtual Education Program - COLT Meeting 2017 (Session 2)

 

David Yeung 3Devendra HiwaseAgnes YONG w labcoat1

Dr David Yeung        Dr Devendra Hiwase     Dr Agnes Yong

            

 

Session 2: TKI resistance / failure

  • When frontline therapy fails 
    (Dr David Yeung)
  • CML - beyond chronic phase
    (Dr Devendra Hiwase)
  • Allograft - still a role in CML?
    (Dr Agnes Yong)

 

VEP Modern Diagnostics: Mutation Screening

 

 We are very grateful for the support of Brandcast media to produce this web stream
VEP Soverini

 

 

  

         

 

 

Mutation Screening:
What is standard of care today and the role of new modalities
Simona Soverini, University of Bologna, Italy 

  • BCR-ABL kinase domain (KD) mutation for optimal patient management
  • When to perform BCR-ABL KD mutation analysis
  • How to perform BCR-ABL KD mutation analysis
  • BCR-ABL KD mutation screening: key issues
  • Next-generation sequencing (NGS): applications
  • NGS for routine BCR-ABL mutatation testing: when?
  • NGS for routine BCR-ABL mutation screening: hurdles
  • Conclusions

Virtual Education Program - COLT Meeting 2017 (Session 1)

Timothy Hughes.png

Prof. Tim Hughes

 

 Session 1: Frontline CML

  • Current clinical issues 
    (Prof. Tim Hughes)

 

Virtual Education Program 2016 Edition (Stopping TKI therapy in CML)

 

 
VEP Mahon 

 

 

  

         

Stopping TKI therapy in Chronic Myeloid Leukemia
Francois-Xavier Mahon, Hospital University of Bordeaux, France 

  • What are the criteria for stopping treatment?
  • What is the definition of molecular relapse triggering re-treatment?
  • Is it safe to stop treatment?
  • Can we cure CML?

Virtual Education Program 2016 Edition (Pediatric CML)

VEP Suttorp                

Treating pediatric Chronic Myeloid Leukemia - an update
Meinolf Suttorp, University Hospital Dresden, Germany 

  • Age specific incidence of CML
  • Value of adult scores in pediatric patients
  • Guidelines for the management of CML in children 
  • Compliance issues with pediatric patients
  • Side effects of TKI treatment in pediatric cohorts